Trastuzumab
|
|
|
- CAS-Nr.
- 180288-69-1
- Englisch Name:
- Trastuzumab
- Synonyma:
- Herceptin;Trastuzumab Beta;RhuMab HER2;TRASTUZUMAB 95 % +;TRASTUZUMAB 98 % +;Trastuzumab USP/EP/BP;TrastuzuMab(Herceptin);Trastuzumab (anti-HER2);Trastuzumab,Stock solution;Trastuzumab - 20mg/ml in PBS
- CBNumber:
- CB61074602
- Summenformel:
- C10H14N6O5
- Molgewicht:
- 298.25536
- MOL-Datei:
- 180288-69-1.mol
|
Trastuzumab Eigenschaften
- storage temp.
- Store at -20°C
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H360 |
Kann die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. |
Fertility (Fruchtbarkeit) |
Kategorie 1 |
Achtung |
![GHS hazard pictograms]() src="/GHS08.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
|
Trastuzumab Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Trastuzumab is used to treat breast cancer. It is effective against tumors that overexpress the HER2/neu protien. As part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu positive cancer.
Indications
The introduction of herceptin (Trastuzumab) into clinical
practice for the treatment of breast cancer marks a
major advance in the use of monoclonal antibody cancer
therapy. Herceptin is a humanized antibody directed
against the HER-2 antigen that is overexpressed
on the tumor cell surface in approximately 25% of
breast cancer patients. HER-2/neu/erbB2 overexpression
marks an aggressive estrogen receptor–negative
form of breast cancer. Therefore, a therapeutic agent
selective for this target is particularly valuable.
Herceptin is administered by intravenous infusion and
in conjunction with paclitaxel can extend survival in
patients with HER-2/neu/erbB2 overexpressing metastatic
breast cancer.Herceptin use is associated with infusion-
related hypotension, flushing and bronchoconstriction,
and skin rash but no bone marrow toxicity.
Herceptin appears to sensitize patients to cardiotoxicity,
an important concern in patients also receiving
doxorubicin.
Einzelnachweise
[1] Hamid Maadi. “Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma.” Cancers (2021).
Trastuzumab Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Trastuzumab Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 104)Lieferanten
180288-69-1()Verwandte Suche:
Tris(pentan-2,4-dionato)eisen(II)
Methylisocyanacetat
Ethylisocyanacetat
Tris(2,2,6,6-tetramethylheptan-3,5-dionato-O,O')dysprosium
Phenylselenol
Tris(2,2,6,6-tetramethylheptan-3,5-dionato-O,O')europium
2-Methylpropylisocyanid
Kupfer(II)-4-oxopent-2-en-2-olat
Aluminiumtris(2,4-pentandionato-O,O')
1,1,3,3-Tetramethylbutylisocyanat
N-Butylisocyanid
(Ethylenbis(nitrilomethylidyn)-2,2'-diphenolato)cobalt(II)
Benzylisocyanid
Dichloro(ethylendiamin)platin
(Pentan-2,4-dionato-O,O')silber
(p-Toluolsulfonyl)methylisocyanid
- TrastuzuMab(Herceptin)
- TRASTUZUMAB 98 % +
- IMMunoglobulin G1,anti-(huMan p185neu receptor) (huMan-Mouse Monoclonal rhuMab HER2 g1-chain), disulfide with huMan-MouseMonoclonal rhuMab HER2 light chain, diMer
- TRASTUZUMAB 95 % +
- Anti HER2, Ig gamma-1 chain C region
- Recombinant humanized anti-HER2 antibody
- RhuMab HER2
- Trastuzumab - 20mg/ml in PBS
- Trastuzumab,Stock solution
- Trastuzumab (anti-HER2)
- Trastuzumab USP/EP/BP
- Herceptin
- Trastuzumab Beta
- Research Grade Trastuzumab(DHC09601)
- EGFR,Trastuzumab,Anti-Human HER2, Humanized Antibody,Epidermal growth factor receptor,HER1,inhibit,ErbB-1,Inhibitor
- Anti-Human HER2, Humanized Antibody
- 180288-69-1
